Prandin (repaglinide), a new oral hypoglycemic for type 2 diabetes

May 1998

You'll soon see Prandin (repaglinide), a new oral hypoglycemicfor type 2 diabetes...co-marketed by Novo Nordisk and Schering.

It's approved for monotherapy...and for use with metformin(Glucophage). It's also being tested with troglitazone (Rezulin).

Prandin is the first drug in a new class...the meglitinides.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

RECOMMENDING vitamin and mineral supplements
tamoxifen to PREVENT breast cancer
Diabetes Prandin (repaglinide), a new oral hypoglycemic for type 2 diabetes
Cholesterol Tricor (fenofibrate) for patients with high triglycerides (TGs)
Cholesterol Niaspan, a new sustained-release niacin
Cholesterol Pravachol (pravastatin) and Zocor (simvastatin) are now approved to prevent STROKE
Lice unusual head lice treatments
Renal & Urology Detrol (tolterodine) for urinary frequency, urgency, or urge incontinence
Renal & Urology DDAVP (desmopressin) TABLETS for bed-wetting
Gastroenterology omeprazole (Prilosec) to prevent and treat NSAID-induced ulcers
Parkinson's Disease changes in the treatment of Parkinson's
Cardiology whether patients with heart failure should get warfarin
Ophthalmology two new eye drops for glaucoma
Ophthalmology several new prescription eye drops for allergies and inflammation
adverse drug reactions